SAREUM HLDGS LS-0125
Sareum Holdings plc, a clinical stage small molecule drug development company, engages in the discovery and development of therapeutic drugs for cancer and autoimmune diseases. The company's lead product is SDC-1801, a TYK2/JAK1 inhibitor which has completed Phase 1 clinical trial for the treatment of autoimmune diseases. It also involves in developing SDC-1802, a TYK2/JAK1 inhibitor, that is in … Read more
Market Cap & Net Worth: SAREUM HLDGS LS-0125 (RYH0)
SAREUM HLDGS LS-0125 (F:RYH0) has a market capitalization of $20.83 Million (€20.30 Million) as of March 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #26026 globally and #2847 in its home market, demonstrating a 7.30% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying SAREUM HLDGS LS-0125's stock price €0.15 by its total outstanding shares 138065173 (138.07 Million).
SAREUM HLDGS LS-0125 Market Cap History: 2021 to 2026
SAREUM HLDGS LS-0125's market capitalization history from 2021 to 2026. Data shows change from $403.90 Million to $20.83 Million (-32.91% CAGR).
SAREUM HLDGS LS-0125 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how SAREUM HLDGS LS-0125's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of RYH0 by Market Capitalization
Companies near SAREUM HLDGS LS-0125 in the global market cap rankings as of March 19, 2026.
Key companies related to SAREUM HLDGS LS-0125 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
SAREUM HLDGS LS-0125 Historical Marketcap From 2021 to 2026
Between 2021 and today, SAREUM HLDGS LS-0125's market cap moved from $403.90 Million to $ 20.83 Million, with a yearly change of -32.91%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €20.83 Million | -4.55% |
| 2025 | €21.82 Million | -49.01% |
| 2024 | €42.80 Million | -50.89% |
| 2023 | €87.16 Million | -23.60% |
| 2022 | €114.08 Million | -71.75% |
| 2021 | €403.90 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of SAREUM HLDGS LS-0125 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $20.83 Million USD |
| MoneyControl | $20.83 Million USD |
| MarketWatch | $20.83 Million USD |
| marketcap.company | $20.83 Million USD |
| Reuters | $20.83 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.